



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵: C07C 215/40, C12N 5/00	A1	(11) International Publication Number: WO 92/12119 (43) International Publication Date: 23 July 1992 (23.07.92)
(21) International Application Number: PCT/US91/09196 (22) International Filing Date: 23 December 1991 (23.12.91) (30) Priority data: 636,353 31 December 1990 (31.12.90) US 724,625 2 July 1991 (02.07.91) US (71) Applicant (for all designated States except US): THE BIOMEMBRANE INSTITUTE [US/US]; 201 Elliott Avenue, West, Seattle, WA 98119 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): KIMURA, Satoshi [JP/US]; IGARASHI, Yasyuki [JP/US]; HAKOMORI, Sen-Itiroh [US/US]; AHMAD, Mahammed, N. [PK/US]; OKOSHI, Hirofumi [JP/US]; HANDA, Kazuko [JP/US]; The Biomembrane Institute, 201 Elliott Avenue West, Seattle, WA 98119 (US).		(74) Agent: MACK, Susan, J.; Sughrue, Mion, Zinn, Macpeak & Seas, 2100 Pennsylvania Avenue, N.W., Washington, DC 20037-3202 (US). (81) Designated States: AT (European patent), BE (European patent), CA, CH (European patent), DE (European patent), DK (European patent), ES (European patent), FR (European patent), GB (European patent), GR (European patent), IT (European patent), JP, LU (European patent), MC (European patent), NL (European patent), SE (European patent), US. Published <i>With international search report.</i>
(54) Title: THE EFFECT OF N,N,N-TRIMETHYLSPHINGOSINE ON PROTEIN KINASE-C ACTIVITY; MELANOMA CELL GROWTH <i>IN VITRO</i> ; METASTATIC POTENTIAL <i>IN VIVO</i> AND HUMAN PLATELET AGGREGATION (57) Abstract The invention relates to a novel compound, compositions and medicaments thereof and a method of inhibiting cell proliferation, platelet aggregation (induced by various factors) and inhibiting malignant phenotypes of tumor cells such as those having a metastatic property, and modulating cell adhesion molecule expression and function using said compound, composition or medicament. N,N,N-trimethylsphingosine shows superior cell proliferation inhibitory and anti-metastatic activity over related compounds.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	RU	Russian Federation
CG	Congo	KP	Democratic People's Republic of Korea	SD	Sudan
CH	Switzerland	KR	Republic of Korea	SE	Sweden
CI	Côte d'Ivoire	LI	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	SU	Soviet Union
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
DE	Germany	MC	Monaco	TG	Togo
DK	Denmark			US	United States of America

THE EFFECT OF N,N,N-TRIMETHYLSPHINGOSINE ON
PROTEIN KINASE-C ACTIVITY;
MELANOMA CELL GROWTH IN VITRO;
METASTATIC POTENTIAL IN VIVO AND
HUMAN PLATELET AGGREGATION

Portions of the research disclosed herein were supported in part by the National Cancer Institute.

This application is a continuation-in-part application of co-pending application U.S. Serial Number 07/724,625 filed 2 July 1991 which is a continuation-in-past application of copending application U.S. Serial Number 07/636,353 filed 31 December 1990.

FIELD OF THE INVENTION

The invention relates to compounds with a profound effect on protein kinase-C activity and mammalian cell proliferation; and methods of using the same.

BACKGROUND OF THE INVENTION

Sphingosine (SPN) is a long chain unsaturated amino alcohol of the formula $C_{18}H_{37}O_2N$ found in cell membranes and in high concentration in nervous tissue. Sphingosine and sphingoid base (a long chain aliphatic base comprising a 1,3-dehydroxy-2-amino group at a terminus and derivatives thereof) have been implicated as inhibitors of protein kinase-C (PK-C) and EGF receptor-associated tyrosine kinase (EGF-RK) (Hannun & Bell, Science, 235, 670, 1987; Hannun, JBC, 261, 12604, 1986; Kreutter et al., JBC, 262,

1632, 1987).

Protein kinase-C activity is related closely to cell growth and recent studies indicate that increased tumorigenicity is correlated with over expression of PK-C_β and PK-C_γ in some experimental tumors (Housey et al., Cell, 52, 343, 1988; Persons et al., Cell, 52, 447, 1988). A mutant PK-C_α induces highly malignant tumor cells with increased metastatic potential (Megidish & Mazurek, Nature, 324, 807, 1989). It would appear that aberrant expression of PK-C may relate to tumor progression.

Recent studies indicate that phospholipids, sphingolipids and metabolic products thereof have an important role in the modulation of transmembrane signaling through PK-C and other membrane-associated kinases, such as EGF receptor-associated tyrosine kinase (Hakomori, JBC, 265, 18713, 1990). For example, PK-C activity is promoted by diacyl glycerol and inhibited by sphingosine (Hannun & Bell, supra; Hannun & Bell, Science, 243, 500, 1989; Merrill & Stevens, Biochem. Biophys. Acta, 1010, 131, 1989).

Sphingosine did not inhibit PK-C in vitro or at concentrations below 100 μM and did not exhibit a stereospecific effect on PK-C (Igarashi et al., Biochem., 28, 6796, 1989). Many of the studies described above employed sphingosine obtained from a commercial source (for example Sigma Chemical Company) and the preparations contained various impurities including 3-O-methylsphingosine, 5-O-methylsphingosine and N-methylsphingosine. The impurities are likely to result from the process of preparation, namely methanolysis of sphingomyelin or cerebroside. Furthermore, in the sphingosine backbone, the D-erythro configuration about the

chiral carbons is often converted to the D-threo configuration.

5 Igarashi et al. (supra) found that the inhibitory effect of sphingosine on PK-C activity is due to: (1) the stereospecific configuration of C1 to C3 (D-erythro configuration required); (2) presence of a long-chain aliphatic group; and (3) perhaps most essential, a negative charge at the primary amino group at C2. If the amino group was
10 N-acetylated, the PK-C inhibitory activity was abolished since the negative charge of an amino group was eliminated by acetylation. However if the anionic character of the amino group was enhanced by N-methylation, the stereospecific PK-C
15 inhibitory activity was enhanced.

Interaction of leukocytes with activated platelets and endothelial cells is an initial step in inflammatory processes and is mediated in part by a family of adhesion molecules known as
20 selectins. Selectins include MEL-14 in mouse and ELAM-1, LAM-1 and GMP-140 (CD62/PADGEM) in man. The selectins are characterized by a similar structural motif consisting of a lectin domain at the N-terminal region, followed by an epidermal growth factor sequence, a complement-regulatory domain, a transmembrane region and a C-terminal domain (Stoolman, Cell, 56, 907, 1989 and Osborn,
25 Cell, 62, 3, 1990). Members of the selectin family bind carbohydrate ligands (see for example, Springer, Nature, 346, 425, 1990; Brandley et al., Cell 63, 861, 1990; Lowe et al., Cell, 63, 475, 1990; and Walz et al., Science, 250, 1132, 1990).

Based on inhibition studies using a variety of glycosphingolipid liposomes, the binding epitopes
35 of both ELAM-1 and GMP-140 expressed on HL60 (a

human promyelocytic cell line) cells were identified as sialosyl-Le^x (Phillips et al., Science, 250, 1130, 1990 and Polley et al., Proc. Natl. Acad. Sci., 1991, in press).

5 Expression of selectins is up-regulated by the inductive effect of lymphokines, tumor necrosis factor (TNF α), bacterial lipopolysaccharides phorbol esters, thrombin and perhaps many other compounds. Leukocytes, together with platelets,
10 thereby are recruited to the inflammatory site. Since tumor cells are capable of activating platelets (see for example, Ugen et al., J. Natl. Canc. Inst., 80, 1461, 1988; Watanabe et al., Canc. Res., 48, 6411, 1988; and Grignani & Jamieson,
15 Blood, 71, 844, 1988), a similar process can be expected to occur during tumor cell adhesion on microvascular endothelia. Thus, the process of tumor cell metastasis may be initiated by selectin-dependent tumor cell adhesion. Although
20 there is no evidence of direct activation of endothelial cells by tumor cells, IL-1 or TNF α -activated endothelial cells have been shown to adhere to a variety of tumor cells (Walz et al., supra).

25 While the regulatory mechanism for expression of selectins is understood poorly, it apparently involves a complex sequence of transmembrane signaling transducers including protein kinase-C, members of the G-protein family (for example, ras,
30 G_s, G_i, G_o etc.) and a 47 kDa phosphoprotein, all of which have been shown to be modulated by glycosphingolipids and sphingosine derivatives. Platelet aggregation and associated ATP secretion are inhibited strongly by trimethylsphingosine
35 (TMS). The phenomenon could result from inhibition

of 47 kDa protein phosphorylation or of phosphoinositide turnover as a membrane signaling pathway in platelets.

5 TMS has a quaternary ammonium structure and displays excellent solubility in aqueous solvents. Although there is no clear evidence that TMS is present or has a role in normal cells, synthetically prepared TMS has lower cytotoxicity and stronger pharmacologic effects on, for example,
10 tumor cells and platelets. Thus, TMS offers advantages over the use of SPN or dimethylsphingosine (DMS) in uses wherein the effect is responsive to sphingoid derivatives.

SUMMARY OF THE INVENTION

15 One object of the invention is to provide a compound and composition for inhibiting metastatic properties of malignant tumor cells, for controlling cell proliferation and for treating various disorders characterized by abnormal cell
20 proliferation.

Another object of the invention is to provide a compound and composition which inhibits protein kinase-C.

25 A further object of the invention is to provide a compound and composition for inhibiting platelet aggregation.

A fourth object of the invention is to provide a compound and composition for inhibiting inflammation.

30 Another object of the invention is to provide a method for making N,N,N-trimethylsphingosine.

A sixth object of the invention is to provide a medicament and method of treating malignancy and

inhibiting metastatic properties of malignant tumor cells.

5 A seventh object of the invention is to provide a compound for modulating cell adhesion molecule expression.

An eighth object of the invention is to provide a compound for treating thrombosis.

10 A ninth object of the instant invention is to provide a method for modulating neutrophil activity.

A tenth object of the instant invention is to provide a method for minimizing tissue damage.

15 Another object of the instant invention is to provide a method for minimizing the deleterious effects of superoxide.

A yet further object of the instant invention is to provide a method for preserving or prolonging the preservation of biologic materials.

20 The and other objects have been attained by the development of a method for making N,N,N-trimethylsphingosine and observations in vitro and in vivo of its efficacy in controlling cell proliferation and inhibiting malignant phenotypes of tumor cells.

25 It has been found that N,N,N-trimethylsphingosine has a higher inhibitory activity on protein kinase-C and metastatic potential of tumor cells than other sphingosine derivatives; inhibits platelet aggregation and tumor-induced platelet interaction; inhibits
30 inflammatory processes; affects the expression of intercellular adhesion molecules and is water soluble. A striking depression of tumor cell metastasis by N,N,N-trimethylsphingosine could be
35 due to its inhibitory activity on protein kinase-C

or on platelet aggregation or on both. TMS also inhibited superoxide (O_2^-) production, as measured by cytochrome C reduction (Superoxide is a highly reactive molecule that can have deleterious biologic effects. Thus, TMS can minimize tissue damage by inhibiting superoxide production.), O_2 consumption, phagokinesis, trans-endothelial migration, 12-myristate 13-acetate (PMA)-induced protein phosphorylation, particularly of proteins with Mr's of about 65kDa and 47 kDa, both of which could be affected via PKC and formyl-methionyl-leucyl-phenylalanine (fMLP)-dependent turnover change in phosphoinositides.

15

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 depicts the structure of N,N,N-trimethylsphingosine and related compounds.

Figures 2A-2C show the effect of sphingosine derivatives on human tumor cell growth. In Figure 2A the growth of human colonic cancer cell line COLO-205 was monitored. In Figure 2B the growth of human lung cancer cell line LU-65 was monitored. In Figure 2C the growth of human gastric cancer cell line MKN-74 was monitored. In each Figure the ordinate represents the percent inhibition of tritiated thymidine incorporation, the solid circles represent sphingosine, the open circles represent N,N-dimethylsphingosine and the triangles represent N,N,N-trimethylsphingosine.

30

Figure 3 depicts the comparative effect of various reagents on tumor cell differentiation. MKN-74 cells were exposed to N,N,N-trimethylsphingosine (open squares),

N,N-dimethylsphingosine (open circles), 8-chloro-cyclic AMP (open triangles), dibutyryl cyclic AMP (solid triangles), sphingosine (solid circles) and hexamethylenebisacetamide (solid squares).

Figures 4A and 4B depict the effect of sphingosine derivatives on protein kinase-C activity in A431 cells. The standard liposome method of Kraft and Anderson (Nature 301, 621, 1983) was used. In Figure 4A the ordinate shows the amount of ^{32}P -ATP that was incorporated into myelin basic protein. In Figure 4B radioactive incorporation into histone III-S is depicted on the ordinate. In both panels SP represents sphingosine, MMS represents N-monomethylsphingosine, DMS represents N,N-dimethylsphingosine and TMS represents N,N,N-trimethylsphingosine.

Figures 5A and 5B depict the effect of N,N,N-trimethylsphingosine (open circles), N,N-dimethylsphingosine (solid circles) and sphingosine (open squares) on two melanoma cell lines, BL6, a highly malignant cell line (in Figure 5A) and F1, a cell line of low malignancy, (in Figure 5B). Cell proliferation was evidenced by tritiated thymidine incorporation into DNA.

Figures 6A-C depict the effect of N,N,N-trimethylsphingosine on lung metastatic deposits after intravenous injection of BL6 cells into mice. Each graph represents the mean and standard deviation of results obtained in 8 animals. In Figure 6A the open bars depict the total number of lung colony deposits; the stippled bars depict the number of lung colonies with a diameter of greater than 1 mm; and the solid bars

depict the number of lung colonies with a diameter of less than 1 mm. Bars 1-3 depict the number of deposits observed 14 days after injection. Bars 4-6 depict the number of lung colony deposits in animals that received BL6 cells and 1 minute later received 0.2 mg of N,N,N-trimethylsphingosine (TMS). Bars 7-9 depict the number of lung colony deposits in animals that received BL6 cells and 0.2 mg of TMS simultaneously. Bars 10-12 depict the number of deposits in animals that received TMS three hours after administration of BL6.

In Figure 6B the number of lung colonies was determined 16 days after treatment, the treatment consisting of varying doses and routes of administration. Bar 1: 3×10^4 BL6 cells i.v. Bar 2: 5×10^6 BL6 cells s.c. Bar 3: 3×10^4 BL6 cells i.v. with 0.5 mg TMS i.p. one hour later. Bar 4: 5×10^6 BL6 cells s.c. with 0.5 mg sphingosine i.v. one hour later. Bar 5: 5×10^6 BL6 cells s.c. with three doses of 0.5 mg TMS i.v. 2, 3 and 4 days later.

In Figure 6C the dose responsiveness of BL6 metastatic potential to TMS is presented. Bar 1 depicts a control comprising colony numbers in lungs of animals wherein 4×10^4 BL6 cells in PBS were injected i.v. Bar 2 depicts the number of colonies in lungs of animals that received 0.1 mg of TMS in 100 μ l PBS, 1 minute after injection of BL6 cells. Bar 3 represents animals treated in the same manner except that the dose of TMS was doubled to 0.2 mg. Bar 4 represents animals that were treated similarly but with 0.5 mg of TMS. Bar 5 represents animals that first were injected with 0.5 mg of TMS in PBS and 1 minute later were injected with 4×10^4 BL6 cells in 100 μ l of PBS.

Sixteen days after treatment, the mice were sacrificed, lungs opened and the number of colonies in the lungs were counted under a dissecting microscope.

5 Figures 7A and 7B depict the effect of N,N,N-trimethylsphingosine (TMS) on platelet aggregation. A 0.45 ml aliquot of human platelet suspension ($3-5 \times 10^5$ platelets per μl of Tyrode's buffer) was incubated with sphingosine or TMS for
10 2 minutes. Then platelet aggregation was induced by the addition of either γ -thrombin (Figure 7A) or adenosine diphosphate (ADP) (Figure 7B) in 0.05 ml. The degree of aggregation was determined in an aggregometer and the data analyzed with an
15 integrated computer (Kyoto Daiichi Kagaku Co. Ltd.).

Figure 8 depicts further the dose response of platelet aggregation by sphingoid. Aggregation of the platelets was induced with 10 nM γ -thrombin.

20 Figure 9 depicts the inhibition of γ -thrombin-induced phosphorylation of 40 kD protein of human platelets by sphingosine and TMS. Human platelets ($3 \times 10^5/\mu\text{l}$) were prelabeled with ^{32}P -phosphoric acid (0.2 mCi/ml) in Tyrode's buffer
25 containing 22 mM trisodium citrate, 1 mg/ml glucose and 3.5 mg/ml bovine serum albumin (pH 6.5) for 75 minutes at 37°C. After centrifugation (600 x g, 10 minutes), the platelets were resuspended in Tyrode's buffer (pH 7.2), aliquoted in plastic
30 tubes and pre-incubated at 37°C for 5 minutes with various concentrations of sphingosine and its derivatives (added as 50% ethanol solutions with a final ethanol concentration of 0.5%). Platelets then were stimulated with thrombin (10 μM). The
35 reactions were stopped after 30 seconds by the

addition of 5 x sample buffer, the samples were boiled and loaded onto 10% SDS-polyacrylamide gels. The proteins were separated electrophoretically. Lane 1-control without stimulation by thrombin; Lane 2-stimulation by 1 μ U/ml of γ -thrombin; Lane 3-stimulated by thrombin but added with 1 μ M TMS; Lane 4-stimulated by thrombin but added with 10 μ M TMS; Lane 5-stimulated by thrombin but added with 20 μ M TMS; Lane 6-stimulated by thrombin but added with 30 μ M TMS; Lane 7-stimulated by thrombin but added with 20 μ M sphingosine; Lane 8-stimulated by thrombin but included addition of 20 μ M N,N-dimethylsphingosine.

Figure 10 depicts the effect of sphingosine derivatives on mouse T-cell line CTLL. Each point is the mean of three replicates. In the figure DMS represents N,N-dimethylsphingosine and TMS represents N,N,N-trimethylsphingosine.

Figures 11A and 11B depict results of representative experiments assessing the percentage of platelets capable of binding an anti-GMP-140 antibody following exposure to various agents. The percentage binding activity was determined in a flow cytometer. SPN is sphingosine; H-7 is 1-(5-isoquinolinylsulfonyl)-2-methylpiperazine; Cal is calphostin-C; TMS is trimethylsphingosine; and DMS is dimethylsphingosine.

Figures 12A and 12B depict results of representative experiments assessing the degree of HL60 binding to platelets. Platelets were exposed to inhibiting compounds (symbols are the same as in the legend to Figures 11A and 11B) and affixed to the wells of a microtiter plate. HL60 cells labelled with tritiated thymidine were introduced into the wells and the amount of bound

radioactivity was assessed.

Figures 13A and 13B depict the effect of various reagents on neutrophil function. In Figure 13A, the effect of TMS on O_2 production was determined by monitoring the superoxide-mediated reduction of cytochrome C (Clifford, Meth. Enz., 105, 393, 1981) by 10^6 neutrophils/ml at OD_{550} and an extinction coefficient of 21000/M/cm in a Beckman DU-50 spectrophotometer. The cells were preincubated for 10 minutes at room temperature with the noted concentrations of TMS prior to stimulation with $1 \mu M$ PMA (time 0). In Figure 13B, it is noted that oxyradical production was inhibited immediately upon exposure to $15 \mu M$ TMS.

Figure 14 depicts the effect of various reagents on neutrophil O_2 consumption. The Clark-type electrode and oxygen monitor were calibrated using air-saturated water according to the manufacturer's recommendations (Y.S.I. Inc., Yellow Springs, OH). A reading of 100% was considered to be equal to the concentration of oxygen in air-saturated water.

DETAILED DESCRIPTION OF THE INVENTION

N,N,N-trimethylsphingosine (TMS) is highly water soluble, particularly at physiologic pH. Thus the compound has a distinct advantage over sphingosine, N-monomethylsphingosine and N,N-dimethylsphingosine, which are less water soluble, as a modulator of cell proliferation.

As used herein, sphingosine indicates sphingosine irrespective of D-, L-, erythro- or threo- configuration.

Also as used herein, "cells" include nucleated

and anucleated structures. Thus, in addition to the 'classical' cells, such as lymphocytes and endothelial cells, biologic structures such as erythrocytes and platelets fall within the ambit of the term.

As used herein, blood or blood products includes whole blood, blood cell preparations, such as packed leukocytes or packed platelets, and the like, outside of the body.

Further as used herein, "synthetically prepared" means a product prepared from commercially available reagents and building blocks and assembled into sphingosine and derivatives thereof by chemical reaction in vitro. Otherwise, sphingosines are prepared from sphingolipids which occur naturally.

Because of the multi-fuctionalized nature of the parent molecule, sphingosine, direct quaternization by exhaustive methylation (Sommer et al., J. Org. Chem. 36, 824, 1971) or reductive methylation using aqueous formaldehyde ($\text{CH}_2\text{O}/\text{NaH}_2\text{PO}_3$) is not always reproducible. Alternatively, N,N,N-trimethylsphingosine can be prepared synthetically from commercially available unsubstituted reagents. For example, unsubstituted sphingosine (Sigma Chemical Company) can be derivatized to form the compound, (4E)-N,N-dimethyl-D-erythro-sphingosine, by a known method (Igarashi et al. JBC, 265, 5385, 1990). The N,N-dimethylsphingosine so obtained undergoes quaternization in almost quantitative yield.

Briefly, about a 37% aqueous solution of formaldehyde (which is about 20 eq.) is added to a solution of D-erythro-sphingenine in acetate buffer ($\text{NaOAc}-\text{AcOH}-\text{H}_2\text{O}$, pH 4.5). The solution is mixed at

room temperature for about 10 minutes and then sodium cyanoborohydride ($\text{NaBH}_3\text{-CN}$) is added three times (at about 3.0, 2.0 and 1.0 eq., respectively). Excess methanol is added sequentially at five minute intervals. The solution is concentrated under a nitrogen stream in an "N-EVAP" (Organomation Assoc., Inc., South Berlin, MA) and the compound extracted with chloroform. When the quantity is large (that is more than about 5-10 mg), the solution is recommended to further concentration under reduced pressure in a rotary evaporator.

The extract can be purified by high pressure thin layer chromatography using standard procedures. By that technique the compound has an R_f of about 0.6 in a buffer comprising $\text{CHCl}_3\text{:MeOH:NH}_4\text{OH}$ in a ratio of 8:2:0.2 by volume.

N,N-dimethylsphingosine prepared as described above was obtained as a colorless syrup in about 80% yield. The molecule has a formula weight of 329.3281 with a formula of $\text{C}_{20}\text{H}_{40}\text{HNO}_2$ as deduced from high resolution mass spectrometry.

Then about 30 milligrams (0.091 m/mol) of (4E)-N,N-dimethyl-D-erythro-sphingosine (DMS) are dissolved in about 1.5 ml of anhydrous chloroform. Freshly distilled iodomethane (a volume of about 170 μl , 2.73 m/mol) is added to the DMS solution and the mixture is stirred in the dark at ambient temperature. (The amount of excess iodomethane is not critical and amounts from 25 to 100% in excess produce satisfactory results.)

The reaction generally is complete in a few hours, although for convenience the mixture is allowed to stand overnight. Progress of the reaction can be monitored by thin layer

chromatography (TLC) using a buffer comprising ethyl acetate:methanol:ammonium hydroxide in a ratio of 20:10:2. After incubation, the precipitated quaternary ammonium salt is diluted with water and then repeatedly extracted with chloroform (3 ml x 4). The organic layer is dried over magnesium sulphate and then concentrated in vacuo.

Practicing the above method, 37 mg (86% yield) of compound was obtained as yellow crystals.

The yellow crystals are dissolved with stirring in an aqueous suspension of preneutralized (pH = 7.00) anion exchange resin (chloride form, Dowex 1 x 2-400, 500 mg) at room temperature for three hours. The mixture then is filtered through a sintered glass funnel and then freeze dried (8 millitorr for two days).

Practicing the above method, 26.5 mg (93% yield) of N,N,N-trimethylsphingosine chloride salt was obtained. The structure of the product was ascertained by proton nuclear magnetic resonance (500 MHz, CDCl₃) and found to contain nine hydrogen groups and a trimethyl derivatized amino group. ¹H-NMR (D₂O) δ 0.88 (t, 3, J = 6.8 Hz, Me), 1.31 (br s, 22, 11xCH₂), 2.08 (q, 2, J = 6.8 Hz, 2xH-6), 3.29 (s, 9 N⁺Me₃), 3.38 (br s, 1, H-3), 4.13 (br s, 2, 2xH-1), 5.57 (dd, 1, J = 3.1 and 3.4 Hz, H-4), and 5.90 (m, 1, H-5). The predicted molecular formula of the compound is C₂₁H₄₄NO₂ with an expected molecular weight of 342.3372 and mass spectroscopy reveals a formula weight of 342.3371 (C₂₁H₄₄NO₂, Δ-0.0003).

The effect of TMS on cell proliferation can be demonstrated in part by exposing various tumor cells to the compound in vitro and in vivo. For

comparison purposes those same test cells also are exposed to sphingosine and N,N-dimethylsphingosine. A ready advantage of TMS over the other two compounds is the water solubility thereof. N,N-dimethylsphingosine and sphingosine are soluble in water as chloride salts and at slightly acidic pH. At neutral or physiologic pH, those solutions tend to form opaque suspensions. TMS is soluble under acidic, neutral or basic conditions providing stable, clear solutions.

An in vitro assay relying on tritiated thymidine incorporation can be used to ascertain the effect of various compounds on cell proliferation. Briefly, tumor cells are seeded in flat bottom 96 well plates (Corning, NY) at a concentration of 2×10^4 cells per well. The cells are cultured for 2 days in DMEM containing various concentrations of sphingoid, which is added as a PBS solution. The medium then is supplemented with tritiated thymidine at a concentration of $0.5 \mu\text{Ci}$ per well. Following a six hour incubation the cells are collected using the PHD Cell Harvester (Cambridge Technology, Cambridge, MA) and amounts of incorporated radioactivity are determined after adding a suitable cell lysing agent and scintillation cocktail, such as ScintiVerse BD (Fisher Scientific, Fairlawn, CA) which performs both functions.

Three cancer cell lines were examined, Colo-205, a human colon cancer line (ATCC No. CCL 222); Lu-65, a lung cancer cell line (T. Yamada et al., Jpn. J. Cancer Res., 76, 967-976 (1985); and MKN-74, a gastric cancer cell line (Motoyama et al., Acta Med. Biol., 27, 49-63 (1979)).

As depicted in Figure 2, in each case TMS was

superior to sphingosine in the ability to inhibit tumor cell growth. (In the figures, the results are presented as the percent of cell growth inhibition relative to control cultures that were not exposed to a test substance.) TMS showed an advantage over DMS although not of the same magnitude. Nevertheless because of the increased efficacy of TMS over DMS, lower amounts were required to effect a specified level of inhibition.

5 The enhanced inhibitory activity of TMS is validated in the data summarized in Figure 3. MKN-74 cells were exposed to cAMP and derivatives thereof and to HMBA, which are known to inhibit tumor cell growth by differentiation induction. Clearly, TMS was the most effective inhibitor of tumor cell growth.

10 In another in vitro assay, the influence of various compounds on PK-C activity can be monitored. Certain tumor cells present high levels of PK-C activity. The human epidermoid carcinoma cell line A-431 (ATCC No. CRL 1555) can be used in a bioassay for PK-C activity as described in Igarashi et al. (supra). Briefly, phosphatidylserine (5 μ g/tube) and 1,2-diolein (0.05 μ g/tube), with or without an appropriate quantity of a sphingosine derivative sample, are added in an organic solvent, ethanol or ethanol/chloroform, to a 1.5 ml tube (Sarstedt) and the mixture is evaporated under a N_2 stream. The lipid mixture is sonicated in about 30 μ l of 20 mM Tris-HCl (pH 7.5) for 30 minutes. The resulting liposomes are supplemented with a buffer mixture comprising 25 mM Tris-HCl (pH 7.5), 10 mM $MgCl_2$, 400 μ M EDTA, 50 μ M EGTA, 500 μ M $CaCl_2$, 200 μ g/ml histone III-S or myelin basic protein and

20 μM γ -[^{32}P]-ATP (2×10^6 cpm) to a final volume of about 90 μl .

5 The reaction is initiated by adding about 10 μl of PK-C, which is prepared from A431 cells as described in Igarashi et al. (supra) or from mouse brain as described in Kikkawa et al. (Biochem. Biophys. Res. Comm., 135, 636, 1986) and containing about 1-2 μg protein, and the mixture is incubated for ten minutes at 30°C. The reaction is
10 terminated by the addition of 1 ml of a 1 mM ATP solution at pH 7.5 containing 25% TCA and 1% BSA. The precipitate is collected by centrifugation, washed twice with 1 ml of 25% TCA, then dissolved in 1 ml of 1 M NaOH containing 0.1% deoxycholate
15 with slight heating (80°C for ten minutes) and counted in a scintillation counter. Reaction mixtures without phosphatidylserine, 1,2-diolein or Ca^{2+} are used as controls.

20 Data from a series of experiments using two different substrates, histone III-S and myelin basic protein, are summarized in Figure 4. Regardless of the substrate, TMS was superior to the other compounds in the ability to inhibit PK-C.

25 Although the data show a superior PK-C inhibitory activity of TMS over the remaining tested compounds, there are other advantages to TMS. Certain cancer cells show a higher metastatic potential and invasive capability than others. For example the BL6 and F10 melanoma cell lines are
30 highly metastatic and invasive. On the other hand, the F1 variant is much less metastatic and invasive (I. R. Hart et al., Amer. J. Pathol., 97, 587-592 (1979); G. Poote et al., Cancer Res. 42, 2770-2778 (1982); F1 and F10 clones from ATCC, CRL 6323 and
35 CRL 6475, respectively).

BL6 and F1 cells were tested in vitro as described above. As shown in Figure 5 TMS was more effective than DMS and sphingosine at inhibiting cell growth. Also BL6 cells were more sensitive to TMS treatment as evidenced by the leftward shift of the TMS curve to lower concentrations.

The effectiveness of TMS in vivo is summarized in the graphs comprising Figure 6. BL6 cells were injected into mice and metastatic deposits in the lung were assessed after various treatments including route and timing of administration. TMS is effective in suppressing lung colonization and tumor development irrespective of route or timing, although early treatment is preferred and repeated treatment is more effective. As revealed in the data summarized in panels B and C, there was a distinct dose responsiveness of lung tumor colonization to TMS.

Another aspect of TMS is the profound effect it has on platelet aggregation (for the purposes of the instant invention, platelets are considered cells). As presented in the data summarized in Figures 7 and 8, TMS inhibited platelet aggregation in a dose-responsive fashion.

Upon thrombin stimulation, a 40 kD platelet protein is phosphorylated. As noted in Figure 9, TMS exposure inhibits phosphorylation of the 40 kD platelet protein. While not wanting to be bound by their statement, the inventors believe that absence of phosphorylated 40 kD protein prevents platelet aggregation.

Platelet activation is of central importance for initiation of numerous biological processes related to hemostasis, inflammation, wound healing and tumor cell metastasis and invasion. There are

many factors and mechanisms which influence platelet activation and many consequences of activation. The selectin GMP-140 binds to neutrophils, HL60 cells or tumor cells which
5 express sialosyl-Le^x. Mechanisms of expression of GMP-140 and its subsequent binding to sialosyl-Le^x are of central importance for initiation of inflammatory processes as well as tumor cell metastasis. GMP-140 expression is down-regulated
10 or blocked by preincubation with TMS. The possibility of a cytotoxic effect of TMS on platelets is excluded clearly by the fact that platelets show normal ristocetin-induced aggregation following incubation with TMS.

15 The utility of TMS is not limited to the suppression of malignant cell growth. Inflammation is characterized in part by a proliferation of lymphoid and myeloid cells. Generally the proliferation serves a beneficial purpose, such as
20 sequestration of foreign antigen or enhancement of restorative capabilities following an insult, but at times can occur abnormally, for example as a result of an autoimmune dysfunction. Thus TMS has utility in controlling cell proliferation of
25 apparently normal cells.

For example, mouse CTLL-2 cells (ATCC No. TIB 214), a T lymphocyte cell line, were plated at 1.5×10^4 cells per well and exposed to test
30 substances. Cell proliferation was monitored by thymidine incorporation. The data of several experiments are summarized in Figure 10. TMS was effective in suppressing CTLL-2 cell growth.

Accordingly, the present invention provides a method for inhibiting growth of human and animal
35 cells comprising the step of exposing said human or

animal cells to a cell growth inhibiting amount of N,N,N-trimethylsphingosine or pharmaceutically acceptable salts thereof.

Because TMS has an inhibitory activity on
5 protein kinase C and other kinases, TMS likely prevents the expenditure of intracellular ATP stores and hence dampens metabolic activity, in addition to the platelet aggregating inhibiting and cell adhesion inhibiting activities described
10 herein. Thus, TMS can be used to preserve or to prolong storage of biologic materials, such as blood products.

For example, it has been shown that TMS retards erythrocyte metabolic activity in vitro
15 under normal blood storage conditions as evidenced by a reduction of erythrocyte enzyme activity. Similar results can be expected for leukocytes and platelets.

Accordingly, TMS can be used as an adjunct to
20 methods and formulations now in use for the preservation or storage of biologic materials. A cell growth inhibiting amount of TMS can be added to the storage medium.

Neutrophils (polymorphonuclear leukocytes)
25 display three major agonist-dependent responses which normally are manifest in three major functions: (i) an exidative burst to produce superoxide (O_2^-); (ii) phagokinetic migratory activity; and (iii) the ability to interact with
30 activated endothelial cells (EC's) and platelets. Mechanisms (ii) and (iii) result in adhesion to EC's and migration through the EC monolayer into the vascular or extravascular matrices. Normally, the functions collectively provide a useful
35 mechanism for disposing of microorganisms in an

inflammatory type response. However, accumulation and overfunction of neutrophils during inflammatory disorders can result in tissue damage and circulatory disturbances.

5 Neutrophil responses are triggered by numerous stimuli, including chemotactic peptides (e.g., formyl-met-leu-phe (fMLP), arachidonate, short-chain diacylglycerol (DAG, C8-DAG) and phorbol esters (e.g., PMA).

10 Superoxide production in neutrophils obtained using art-recognized methods, for example, see Nojiri et al., Blood, 64, 534, 1984, as determined by reduction of cytochrome C, is inhibited by TMS in a dose-dependent manner (Figures 13A and 13B).
15 TMS (20 μ M) completely abolishes superoxide production. (The reduction of cytochrome C is monitored using known methods, such as the method of Clifford, Meth. Enz., 105, 393, 1981. O_2 consumption of neutrophils, as determined by
20 electrical conductivity using an oxygen monitor and micro O_2 chamber assembly (Y.S.I. Inc., Yellow Springs, OH), is enhanced significantly by PMA. The PMA-dependent enhancement of O_2 consumption is inhibited strongly by TMS (Figure 14).

25 The phagokinetic activity of neutrophils on gold sol-coated plates can be determined by a technique essentially as taught in Albrecht-Buehler (Cell, 11, 395, 1977). Phagokinetic activity is suppressed significantly by as little as 1.5 μ M TMS
30 and completely suppressed by 4.5 μ M TMS. The TMS-dependent inhibitory effect is reversed completely when the culture medium is replaced with TMS-free medium. Thus, the inhibitory effect of
35 TMS on phagokinetic activity is not dependent on cytotoxicity.

A characteristic of neutrophils is the ability to adhere to activated EC's and to migrate through the EC monolayer into the vascular or extravascular matrix. The effect of TMS on neutrophil interactions with EC's and their subsequent trans-endothelial migration thereof can be monitored in vitro using human umbilical endothelial cells (HUVEC's) (Luscinskas et al., J. Imm., 146, 1617, 1991). Neutrophils are added to a HUVEC monolayer and neutrophil-HUVEC interactions are assessed microscopically following fixation, embedding and staining of monolayer sections.

Under physiological conditions, neutrophils are able to migrate into the collagenous matrix through the EC monolayer. When EC's are activated with IL-1 β in M199 medium for 4 hours, neutrophils migrate into the collagenous matrix within 90 minutes. Neutrophil migration is inhibited strongly by pre-treatment of neutrophils with 8 μ M TMS, and completely inhibited by pre-treatment with 25 μ M TMS.

The dose-dependent inhibitory effect of TMS and other protein kinase inhibitors on migration of neutrophils through the IL-1 β -activated EC monolayer is summarized in Tables I and II. TMS (15 μ M) greatly reduces the number of cells migrating through the EC monolayer without affecting the viability of the cells. Calphostin C (5 μ M), 200 μ M H7 and 2 μ M staurosporine produce similar cytotoxic effects on neutrophils although staurosporine and calphostin C produce striking morphologic damage to EC's (Tables III and IV).

TMS (15 μ M) shows no significant cell cytotoxicity whereas 15 μ M SPN and 15 μ M DMS show 12-13% cytotoxicity. At 25 μ M, SPN and DMS produce

TABLE I
Suppression of phagokinetic activities by
protein kinase inhibitors

5	Inhibitor†	Area Swept	N
	CONTROL	100±25%*	178
	TMS (4.5 µM)	16±18	93
	SPN (4.5 µM)	14± 7	72
	DMS (4.5 µM)	26±25	132
10	H-7 (200 µM)	27± 6	75
	Staurosporine(0.2 µM)	13±12	68
	Calphostin C (0.5 µM)	39±11	65
	Ceramide (4.5 µM)	109±25	62

15 *mean ± sample standard deviation

§ The area swept by neutrophils was determined in photographs of the monolayers. The regions cleared by neutrophil movement were then cut out and weighed.

20 † H-7 was obtained from Seikagaku Kogyo (Tokyo, Japan); staurosporine and calphostin C were obtained from Kamiya Biochemical Co. (Thousand Oaks, CA); and ceramide was obtained from Sigma.

25

TABLE II
Effect of TMS and ceramide on neutrophil
transmigration

	<u>μM</u>	<u>TMS</u>	<u>Ceramide</u>
5	0	100 \pm 17*	100 \pm 17
	4	96 \pm 18	92 \pm 24
	8	66 \pm 28	ND
	15	41 \pm 8.7	87 \pm 27
10	25	6.8 \pm 4.1	ND
	45	1.2 \pm 1.2	83 \pm 16

* mean \pm sample standard deviation (N = 25)

15 Cross-sections (2 μ m) of the collagen bed with HUVEC's and neutrophils were observed using a Zeiss light microscope with KPL W10 and Ph2 Neofluar 16 lenses. The number of cells transmigrated were counted for each view.

ND = Not Done

TABLE III

Effect of various PKC inhibitors on neutrophil transmigration through endothelial monolayers

	<u>Effectors</u>	<u>Number of Cells/View</u>	<u>Viability</u>
5	control	100±14*	94±2.1
	15 μ M TMS	39±17	97±2.9
	15 μ M SPN	36±12	87±5.3
	200 μ M H-7	38±12	79±7.1
10	2 μ M Staurosporine	52±25	83±3.6**
	5 μ M Calphostin C	19±8.9	46±5.5**

*mean \pm sample standard deviation (N = 25)

**significant morphologic damage to HUVEC's.

TABLE IV

Recovery of phagokinetic activity from effectors*

	Treatment	Area Swept	N
5	control (w/o further incubation)	100±25†	178
	control (0.1% ethanol)	92±30	118
	TMS (12 µM)	92±34	77
	SPN (12 µM)	42±24	86
	DMS (12 µM)	32±19	112

†mean ± sample standard deviation

*Neutrophils were pre-incubated with 12 µM of the noted treatment for 10 minutes in test tubes and then distributed to the monolayers. The treatment reagents were diluted 200-fold following that procedure.

TABLE V
Viability of neutrophils

	μ M	Ceramide	TMS	SPN	DMS
5	0	97 \pm 3*	97 \pm 3	97 \pm 3	97 \pm 3
	5	98 \pm 2	98 \pm 2	95 \pm 3	96 \pm 3
	15	96 \pm 1	97 \pm 3	87 \pm 5	88 \pm 8
	25	-	83 \pm 6	53 \pm 18	29 \pm 5
	45	91 \pm 3	63 \pm 8	5 \pm 5	0 \pm 1

* mean \pm sample standard deviation (N=8)

The concentration of neutrophils ranged from 0.8 to 1.7×10^6 /ml. The viability was evaluated by trypan blue exclusion assay. The cell suspension in RPMI 1640 with glutamate and pyruvate without FCS was incubated at 37°C for 10 min with effectors. The aliquot was mixed with an equal amount of trypan blue solution and immediately counted under a Nikon light microscope.

major cytotoxic damage to neutrophils whereas the effect of TMS is negligible (Table V).

When neutrophils, metabolically labeled with [³²P]sodium phosphate (2 mCi) for 1 hr to enrich intracellular ATP, are stimulated with 1.5 μ M PMA, two protein bands following SDS-PAGE show greatly enhanced phosphorylation. The proteins have molecular weights of about 47 kDa and 65 kDa. When neutrophils are pre-incubated with 15-45 μ M SPN, DMS or TMS and then stimulated with PMA, phosphorylation of both proteins is diminished significantly. The inhibitory effect on phosphorylation is observed within 2 minutes of incubation. Because phosphorylated 47 kDa and 65 kDa proteins appear to be direct substrates of PK-C, the inhibitory effects of SPN, DMS, and TMS may occur via an inhibitory effect on PK-C.

Metabolic incorporation of [³²P]sodium phosphate (4 mCi) into phosphatidylinositol (PI), phosphatidylinositol-4-phosphate (PIP) and phosphatidylinositol-4,5-bis-diphosphate (PIP₂) is enhanced by chemotactic peptide fMLP (1 μ M). The fMLP-dependent enhancement is suppressed strongly by pre-incubation of neutrophils with 5 μ M TMS. Relative intensity of fMLP-induced labeling in PIP and PIP₂, and the effects of SPN, DMS and TMS on metabolic incorporation of ³²P into PIP and PIP₂ are summarized in Table VI.

TABLE VI
Effect of TMS, DMS and SPN on phosphoinositide turnover

	Effector	PIP	PIP2
5	control	100	100
	1 μ M FMLP	182 \pm 39*	147 \pm 32
	5 μ M TMS plus FMLP	127 \pm 19* ²	98 \pm 7.2* ³
	5 μ M SPN plus FMLP	174 \pm 37	128 \pm 13
10	5 μ M DMS plus FMLP	146 \pm 27	109 \pm 17* ¹

*, mean \pm sample standard deviation (N = 6)

*1, p < 0.05

*2, p < 0.02

15 *3, p < 0.01

20 Amount of ³²P in PIP and PIP2 was measured using TLC separation. The spots on TLC plates were scraped off and the radioactivity therein was measured with a Beckman scintillation counter. Each spot was compared as to intensity with the identical spot of the control sample.

The present invention further provides medicaments and treatments for inhibiting growth in human and animal cells and aggregation of human and animal platelets comprising:

- 5 (1) a therapeutically effective amount of N,N,N-trimethylsphingosine or pharmaceutically acceptable salts thereof; and
- 10 (2) a pharmaceutically acceptable carrier, diluent or excipient.

The medicaments and methods are applicable both for in vitro and in vivo applications. Specific uses include treatment of malignancies, benign tumorous growths, inflammation, other
15 manifestations of immune system dysfunction and when the immune system inappropriately or excessively responds to a stimulus.

The medicament comprises an effective amount of TMS and a pharmaceutically acceptable carrier,
20 diluent or excipient. The effective amount of TMS can be determined using art-recognized methods, such as by establishing dose-response curves in suitable animal models, such as described herein or in non-human primates, and extrapolating to human;
25 extrapolating from suitable in vitro data, for example as described herein; or by determining effectiveness in clinical trials.

Trimethylsphingosine also has profound effects on cell adhesion molecules. The effect is
30 evidenced by the inhibition of cell adhesion molecule expression by platelets. For example thrombin induces expression of GMP-140 in platelets. However, exposure of platelets to TMS inhibits GMP-140 expression. Thus, TMS will be
35 useful in disorders that rely on cell adhesion

molecule dependent-processes. As noted above, GMP-140, as does ELAM-1, binds sialosyl-Le^x. Thus, TMS will find utility in preventing lymphocyte-endothelial cell adhesion and subsequent interactions between cells such as the development of an inflammatory state at a site of injury.

Suitable doses of medicaments of the instant invention depend upon the particular medical application, such as the severity of the disease, the weight of the individual, age of the individual half-life in circulation etc., and can be determined readily by the skilled artisan. The number of doses, daily dosage and course of treatment may vary from individual to individual.

TMS can be administered in a variety of ways such as orally, parenterally and topically. Suitable pharmaceutically acceptable carriers, diluents, or excipients for the medicaments of the instant invention depend upon the particular medical use of the medicament and can be determined readily by the skilled artisan.

The medicament can take a variety of forms such as tablets, capsules, bulk or unit dose powders or granules; may be contained within liposomes; or may be formulated into solutions, emulsions, suspensions, ointments, pastes, creams, gels, foams or jellies. Parenteral dosage forms include solutions, suspensions and the like. The medicament is likely to contain any of a variety of art-recognized excipients, diluents, fillers etc. Such subsidiary ingredients include disintegrants, binders, lubricants, surfactants, emulsifiers, buffers, moisturizers, solubilizers and preservatives. The artisan can configure the appropriate formulation comprising TMS and seeking

guidance from numerous authorities and references such as "Goodman & Gilman's, The Pharmaceutical Basis of Therapeutics" (6th ed., Goodman et al., eds., MacMillan Publ. Co., NY, 1980).

5 In body sites that are characterized by continual cell growth or require cell growth inhibition because of dysfunction and are relatively inaccessible, TMS can be administered in a suitable fashion to assure effective local
10 concentrations. For example, TMS may be injected in a depot or adjuvant, carried in a surgically situated implant or reservoir that slowly releases a fixed amount of TMS over a period of time or may be complexed to recognition molecules with the
15 capability of binding to the site presenting with abnormal cell growth. An example of such a contemplated scenario is a recognition molecule that is an antibody with binding specificity for a bone marrow specific antigen wherein said marrow
20 specific antibody is complexed to TMS, said complex administered to a patient with leukemia.

Certain aspects of the invention are described in the following non-limiting Examples. Unless
25 otherwise indicated, all amounts and measures are in w/v or v/v relationships.

EXAMPLE 1

Platelets were isolated from platelet-rich plasma (purchased from the Oregon Red Cross, Portland, OR). Contaminating erythrocytes were
30 removed by centrifugation (80 x g for 10 minutes). Platelets were obtained by centrifugation (300 x g for 10 minutes), washed once in Tyrode's buffer (pH 6.5) containing 22 mM trisodium citrate and

0.35% (w/v) BSA and resuspended in the same buffer to obtain a concentration of $1-2 \times 10^9$ platelets/ml. All procedures were performed at room temperature.

5 A suspension of platelets (3.5×10^8 /ml) in Tyrode's buffer was preincubated with various inhibitor compounds (H-7 is [1-(5-isoquinolinylsulfonyl)-2-methylpiperazine, a synthetic protein kinase-C inhibitor purchased from Seikagaku America Inc., St. Petersburg, FL],
10 calphostin-C [a synthetic protein kinase-C inhibitor obtained from Dr. Saitoh, Kyowa Hakko Co., Ltd., Machida, Tokyo, Japan], sphingosine [purchased from Sigma, St. Louis, MO] and dimethylsphingosine and trimethylsphingosine
15 [synthesized according to Igarashi et al., Biochem., 28, 6796, 1989]) followed by addition of thrombin or ADP (both purchased from Sigma). Platelet aggregation was evaluated by transmittance change using an aggregometer (Chrono-log Corp.,
20 Havertown, PA) equipped with a computer analyzer. TMS inhibited platelet aggregation.

EXAMPLE 2

GMP-140 expression was determined by (i) flow cytometry with mAb AC1.2, which is directed to
25 GMP-140 and obtained from Dr. Furie (Tufts Univ. Sch. Med., Boston, MA) and (ii) adhesion of HL60 cells on platelet-coated solid phase.

A suspension of platelets (1×10^8 /ml) in Tyrode's buffer was preincubated with inhibitor at
30 pH 7.2, 37°C, for 5 minutes, then supplemented with activator, either thrombin (final concentration 1 U/ml) or phorbol 12-myristate 13-acetate (PMA) (final concentration 10^{-7} M), and the mixture was

incubated at 37°C for 10 minutes. Platelets were fixed with an equal volume of 2% (w/v) paraformaldehyde in PBS and washed 2 times with PBS containing 1% (w/v) BSA.

5 The paraformaldehyde-fixed platelets were incubated with 50 μ l of mAb AC1.2 (2.5 μ g/ml) at room temperature for 30 minutes. Platelets were washed 2 times with PBS containing 1% (w/v) BSA, supplemented with 50 μ l of fluorescein
10 isothiocyanate-labeled goat anti-mouse Ig (purchased from Tago Co., Burlingame, CA), incubated at room temperature for 30 minutes and again washed 2 times with PBS containing 1% (w/v) BSA. As a negative control, paraformaldehyde-fixed
15 platelets were incubated with mouse IgG instead of mAb AC1.2 and treated as described above.

 The platelets were analyzed in an Epics flow cytometer (Coulter Corp.) with suitable gating. To calculate the inhibitory effect of various
20 reagents, the mean fluorescence intensity of resting platelets (obtained on incubation of platelets without activator) was subtracted from the value for the activated platelet sample.

 Results of representative experiments are summarized in Figures 11A and 11B. TMS at 10-20 μ M
25 strongly inhibited GMP-140 expression. While DMS did not inhibit thrombin- or ADP-induced platelet aggregation as well as did TMS, DMS strongly inhibited thrombin-induced GMP-140 expression. SPN
30 and H-7 produced no inhibition of GMP-140 expression. Calphostin-C produced weak inhibition at 10-20 μ M [The compound has been reported to inhibit protein kinase-C at a concentration of 0.05 μ M in vitro (Tamaoki & Nakano, Bio/Tech., 8,
35 732, 1990).].

Similar results were obtained for PMA-induced platelets, i.e., both TMS and DMS, at 10-20 μ M, strongly inhibited GMP-140 expression (Figure 11B). Neither SPN nor H-7 showed inhibition, even though
5 H-7 was reported to inhibit PKC at a concentration of 15 μ M (Tamaoki & Nakano, supra).

EXAMPLE 3

HL60 (a human promyelocytic cell line available from the ATCC under accession number CCL
10 240) adhesion on resting or activated platelet-coated solid phase was evaluated as follows. Each well of a 48-well plate (Costar Scientific, Cambridge, MA) was filled with a poly-L-lysine solution (100 μ g/ml in PBS) and
15 incubated for 1 hour. Each well then was washed with PBS and then 150 μ l of PBS containing 6×10^7 resting or activated platelets were added to each well and the plate was incubated for 1 hour. Plates were centrifuged (300 x g for 7 minutes) and
20 incubated a further 30 minutes at room temperature. Bound platelets were fixed by addition of 0.1% (w/v) glutaraldehyde in PBS for 2 minutes at 4°C. Each well was washed with 10 mM glycine in PBS and plates were incubated with 5% (w/v) BSA
25 containing 0.1% (w/v) sodium azide, 10 mM glycine in PBS for 1 hour at room temperature.

After washing with culture medium (RPMI 1640 containing 5% (v/v) FCS), 1×10^6 HL60 cells labeled with [3 H]thymidine were added to each well. HL60
30 was maintained in RPMI 1640 medium (purchased from Irvine Scientific, Santa Ana, CA) supplemented with 10% FCS (Hyclone, Logan, UT). (Radiolabeling of HL60 cells used for cell adhesion assays was

performed by incubating cells with 2 μ Ci/ml of [3 H]thymidine overnight.) After incubation for 45 minutes at room temperature, unbound cells were aspirated and wells were washed once with medium (RPMI 1640 containing 5% (v/v) FCS), bound cells were detached with 0.05% (w/v) trypsin-0.02% (w/v) EDTA (Irvine Scientific) in PBS and the levels of radioactivity in each well were determined in a liquid scintillation counter.

Results from representative experiments are presented in Figures 12A and 12B. For both thrombin- and PMA-stimulated platelets, HL60 cell binding was inhibited strongly by TMS and DMS, but minimally inhibited by SPN. Binding of HL60 cells to activated platelets is considered to depend solely on recognition by GMP-140 of sialosyl-Le^x expressed on HL60 cells since the binding was inhibited specifically by liposomes containing sialosyl-Le^x but not by liposome containing other glycosphingolipids.

EXAMPLE 4

Human neutrophils were obtained from normal male adults. Heparinized peripheral blood was mixed gently with an equal amount of 1% dextran solution in PBS in a 60 ml injection syringe. The mixture was allowed to sit vertically for 60 to 90 minutes at 37°C. The upper phase, which is rich in white blood cells, was mounted gently on the same volume of Ficoll-Paque (Pharmacia LKB, Uppsala, Sweden) in Falcon 2095 plastic test tubes (Becton Dickinson Labware, Lincoln Park, NJ). Centrifugation at 450g for 30 min at 4°C brought the neutrophils to the bottom of the tubes. The

upper phase and interface, which contains lymphocytes, were removed carefully by aspiration.

Contaminating erythrocytes were removed from the cell pellet by hypotonic lysis by resuspending the cell pellet in ice-cold distilled water for 30 sec then adding an equal volume of ice-cold 1.8% NaCl solution. After centrifugation at 80g for 10 min, the cells were resuspended with a suitable buffer or media.

The final preparation consisted of more than 98% neutrophils, as determined by Wright-Giemsa staining. The suspension was stored at 4°C and used within 3 hr.

EXAMPLE 5

Superoxide production by neutrophils was quantitated by monitoring superoxide-mediated reduction of cytochrome C (Clifford, supra, in which the reduction is manifest as an increase in absorbance at 550 nm at an extinction coefficient of 21000/M/cm). Measurements were carried out with a Beckman DU-50 spectrophotometer at 37°C using $\approx 1 \times 10^6$ neutrophils per ml. The cells were allowed to equilibrate for 10 min with TMS, or other effectors, prior to addition of 1 μ M of PMA.

TMS had a profound effect on neutrophil superoxide production.

EXAMPLE 6

O₂ consumption was measured using a Clark-type electrode with a Y.S.I. model P300 biological oxygen monitor and a micro oxygen chamber assembly (Y.S.I. Inc., Yellow Springs, OH). Assays were

performed at 37°C with $\approx 6 \times 10^6$ neutrophils per ml in a total volume of 600 μ l. The cell suspensions, in Eppendorf test tubes, were warmed at 37°C for several minutes before being applied to the microchamber. Effectors were injected carefully using a Hamilton syringe and stirred well with a microstirrer at a speed of ≈ 240 rpm. The cell suspensions were pre-incubated with effectors for 5 min prior to addition of PMA to a final concentration of 1.0 μ M.

TMS had a noted effect on neutrophil O_2 consumption.

EXAMPLE 7

Freshly purified neutrophils ($\approx 8 \times 10^7$ cells) were pre-incubated at 37°C with 2 mCi of $Na_2H[^{32}P]O_4$ in a buffer containing 0.1% lipid-free BSA-HEPES (10 mM pH 7.4, 136 mM NaCl, 4.9 mM KCl, 5.6 mM glucose and 0.33 mM $CaCl_2$) for 60 min in a shaking waterbath. Excess unbound components were removed by centrifugation and the pellets were resuspended in the same buffer, repeating twice. The cells then were divided into 7 treatment groups, each containing $\approx 1 \times 10^7$ cells in a total volume of 0.4 ml. TMS, SPN or DMS was added to a suspension and incubated at 37°C for 10 min, followed by addition of PMA to a final concentration of 1.5 μ M. Two minutes later, the reaction was terminated by adding 0.1 ml of Laemmli's sample buffer and 20 mM EDTA, followed by heating at 100°C for 5 min. Aliquots were separated through 10% sodium dodecyl sulfate gels using known procedures. ^{32}P incorporation was visualized by autoradiography.

TMS had an affect on phosphorylation of

specific proteins related to protein kinase C metabolism and activity.

EXAMPLE 8

Freshly purified human neutrophils
5 (1.3 x 10⁸/ml in 0.1% BSA-HEPES 10 mM buffer:
pH 7.45, 136 mM NaCl, 4.9 mM KCl, 5.6 mM glucose
and 0.33 mM CaCl₂) were incubated at 37°C with 4 mCi
of NaH₂[³²]PO₄ for 90 min in a shaking waterbath.
After incubation, the cells were washed and
10 resuspended in the same buffer at a concentration
of 1 x 10⁷ cells/ml. Each suspension (1 ml) then
was pretreated with TMS, SPN or DMS, or equal
volume of 50% ethanol, for 10 min at 37°C. Then
keeping the same temperature, fMLP was added to a
15 final concentration of 1.0 μM. Two minutes later,
the reaction was terminated by adding 3.75 ml of
chloroform/methanol (1:2) to each cell suspension,
followed by sonication for 15 min. An additional
1.25 ml of chloroform, 1.25 ml of water and 50 μl
20 of acetone were added and the total mixture was
mixed and left overnight.

Following centrifugation of the mixture, the
phospholipids were extracted by Folch's partition
method, taking the lower phase from the cell
25 lysate. After evaporation of the lower phase,
≈10000 cpm of phosphate compounds were mounted on
a Whatman HP-KF (Whatman, Maidstone, England)
silica gel TLC plate, previously impregnated with
methanol/water (2:3) containing 1% potassium
30 peroxalate (Sigma, St. Louis, MO). The TLC plate
was developed with control phospholipids, in a
solvent comprising chloroform/methanol/4M NaOH at
a ratio of 45:35:10 and containing 0.1% CDTA

(trans-1,2-diaminocyclohexane-N,N,N',N'-tetraacetic acid) for 65 min at 37°C. The bands were identified by staining the control phospholipids with primuline and visualization under ultraviolet light. Autoradiography was performed with Kodak diagnostic film GBX-2 (Rochester NY) by exposing overnight at 37°C.

TMS suppressed fMLP induced phosphorylation of phosphatidyl inositols.

10

EXAMPLE 9

Phagokinetic activity was observed by tracing tracks of neutrophils moving on a glass substrate covered with gold colloid particles. The technique was described originally by Albrecht-Buehler, supra, using 3T3 and other cell lines. Briefly, 22 x 22 mm square glass coverslips (Corning Glass Works, Corning, NY) were dipped for 1 min into 1% BSA prepared in Milli Q water. The BSA solution was prepared fresh each day and passed through 0.20 μ m Nalgene filters (Nalgene Labware Division, Rochester, NY).

The coverslip then was drained by touching a Kim-wipe paper towel to its edge, dipped into 100% ethanol and rapidly and completely dried in a 85°C hot airstream. The coverslip was placed in a 3.5 cm Falcon plastic dish. Then 5.4 ml of AuCl₃H and 18 ml of 36.5 mM Na₂CO₃ were added to 33 ml of distilled water and heated. Immediately after reaching the boiling point, 5.4 ml of 0.1% formaldehyde in water were added quickly and mixed. The suspension of gold particles forming a brownish color was distributed immediately onto the dish (2 ml each) and the coverslip was incubated for

2 hr at 37°C.

Particle-coated coverslips were washed in PBS, then twice in RPMI 1640 and finally put in another 3.5 cm Falcon plastic dish containing 2 ml of RPMI 1640 with glutamate and pyruvate. The coverslips were stored at 4°C and used within 24 hr after preparation.

The freshly-purified neutrophils (1×10^6 cells/plate) were added onto the colloid-coated coverslip. TMS and other effectors were added into the medium on the plate. As a control, the solvent of the effectors (50% ethanol) was added at an equal amount. At that concentration (0.1%), ethanol brought no significant effect on neutrophil activities. To observe cell recovery from exposure to the effectors, neutrophils (2×10^5 cells/ml) were pre-incubated at 37°C with 12 μ M of TMS, SPN and DMS, then distributed to the dish dropwise, diluting the effectors 200-fold. Incubation was conducted under 5% CO₂ at 37°C for 2 hr and terminated by adding 200 μ l of 10% formaldehyde. Microscopic examination of each plate was performed with a Nikon microscope, connected to a Polaroid camera for recordings. Phagokinetic activity was measured by tracing the track of a neutrophil. The track was recorded with photographs, then the area was measured by cutting and weighing the swept area.

TMS inhibited neutrophil migration without an adverse effect on cell viability.

EXAMPLE 10

HUVEC's and culture media were purchased from

Cell Systems (Kirkland, WA). The cells were maintained and cultured as described in Lusciuskas et al., supra, with some modifications. Briefly, HUVEC's were maintained in 10 ml tissue culture
5 flasks on a collagen type I bed obtained from rat tail (Upstate Biotechnology Inc, Lake Placid, NY) with CS-complete medium, CS-growth factor and CS-AF-1 (Cell Systems). Cells became confluent within 2 to 4 days when incubated in 5% CO₂ at 37°C.

10 For the transmigration assay, thick gels were formed in 24-well tissue culture plates. Preparation of the gel solution was carried out at 4°C. Eight parts of collagen solution (Vitrogen 100, from bovine tendon which contained
15 less than 5 ng/ml endotoxin; Celtrix Labs, Palo Alto, CA), one part of 10x RPMI and one part of alkaline solution (2.2 g NaHCO₃ in 100 ml of 0.05 N NaOH and 200 mM HEPES) were mixed gently and distributed at 0.7 ml/well. The solution was left
20 for 4 hr at 37°C to eliminate air bubbles, then allowed to gel in a 37°C oven for 3 hr. The wells were washed with 1.0 ml of CS-complete medium with attachment factors at least 4 times and every 3 to 6 hr during further incubation at 37°C in 5% CO₂.

25 HUVEC's at a passage level of less than 3 were detached from 10 ml tissue culture flasks with 3 ml of Trypsin-EDTA at 37°C for 30 to 60 sec. Immediately, 3 ml of M199 with 20% heat-inactivated FCS was added. Cells were collected by
30 centrifugation. The pellet was resuspended in 10 ml of CS-complete medium with attachment factors. Homogeneous cell suspensions were plated at 0.7 ml to each well and the plates were incubated for 3 hr at 37°C. The supernatant, which
35 contains dead cells, was aspirated carefully and

fresh complete medium with attachment factors was added. Under those conditions, the HUVEC's formed confluent monolayers in which intracellular junctions consistently showed silver-staining within 24 hr after plating and the cells retained that property after a day in culture.

5 The HUVEC monolayer in 24-well tissue culture plates were washed with M199 without FCS, then incubated with 1 ml/well of IL-1 β (Boehringer Mannheim Biochemical Products, Indianapolis, IN) dissolved in M199 with 1% heat-inactivated FCS (HIFCS) at 10 U/ml. The plates were incubated at 10 37°C, 5% CO₂ for 4 hr then washed gently with 1 ml of M199. The purified neutrophil suspension (1.5 x 10⁶ cells/ml) in M199 containing 1% HIFCS was 15 pre-incubated with TMS, or other effectors, for 10 min at 37°C. After aspirating the media in the well, 0.5 ml of the neutrophil suspension were added onto the HUVEC monolayer. The tissue culture 20 plate was incubated for 90 min at 37°C.

The culture was terminated by gently aspirating the cell suspension, adding 1 ml of 10% formaldehyde in PBS and stored at 4°C overnight for fixation. The edge of the collagen bed was cut 25 with a small spatula along the wall 2 hr before removal from the well. The collagen bed, which has HUVEC's on the surface and transmigrated neutrophils within was embedded in paraffin, sectioned and followed by staining with 30 hematoxylin-eosin for microscopic examination.

TMS affected neutrophil migration without effecting cell viability.

All references cited herein are herein incorporated by reference.

While the invention has been described in detail and with reference to certain embodiments thereof, it would be apparent to one skilled in the art that various changes and modifications can be made without departing from the spirit and scope thereof.

What is claimed is:

1. N,N,N-trimethylsphingosine.
2. A pharmaceutically acceptable salt of N,N,N-trimethylsphingosine.
3. A medicament comprising:
 - (a) a cell proliferation inhibiting amount of N,N,N-trimethylsphingosine or pharmaceutically acceptable salt thereof; and
 - (b) a pharmaceutically acceptable carrier, diluent or excipient.
4. A composition comprising:
 - (a) a cell proliferation inhibiting amount of N,N,N-trimethylsphingosine; and
 - (b) a carrier, diluent or buffer.
5. A method for inhibiting cell proliferation comprising contacting cells with a cell growth inhibitory amounts of N,N,N-trimethylsphingosine.
6. The method of claim 5, wherein said contacting step is performed in vitro.
7. The method of claim 5, wherein said contacting step is performed in vivo.
8. The method of claim 5, wherein said cells are cancer cells.
9. The method of claim 5, wherein said cells are of the immune system.
10. An N,N,N-trimethylsphingosine made by the process comprising the steps of:
 - (a) dissolving (4E) - N,N-dimethyl-D-erythro-sphingosine in an anhydrous organic buffer to

produce a solution;

(b) dissolving in said solution of step (a) freshly distilled iodomethane to produce a mixture;

5 (c) incubating said mixture of step (b) to produce a N,N,N-trimethylsphingosine product; and

10 (d) separating said N,N,N-trimethylsphingosine produced therefrom.

11. The N,N,N-trimethylsphingosine of claim 10, wherein said organic buffer is anhydrous chloroform.

12. The N,N,N-trimethylsphingosine of claim 10, wherein said iodomethane is present in 25-100% excess.

13. The N,N,N-trimethylsphingosine of claim 10, wherein said mixture of step (c) is incubated overnight.

14. The N,N,N-trimethylsphingosine of claim 10, wherein said process further comprises the step of:

5 (e) stirring said product of step (d) with neutralized anion exchange resin to produce halogen derivatized N,N,N-trimethylsphingosine; and

10 (f) separating said halogen derivatized N,N,N-trimethylsphingosine produced therefrom.

15. A method of synthesizing N,N,N-trimethylsphingosine comprising the steps of:

5 (a) treating N,N-dimethylsphingosine with iodomethane to produce a precipitate; and

(b) extracting said precipitate with chloroform.

16. The method of claim 15, wherein said N,N-dimethylsphingosine is synthesized by a process comprising the steps of:

- 5 (a) treating sphingenine with formaldehyde;
- (b) exposing said treated sphingenine to sodium borohydride and excess methanol to produce N,N-dimethylsphingosine; and
- 10 (c) extracting said N,N-dimethylsphingosine with chloroform.

17. A method of inhibiting platelet aggregation comprising exposing platelets to an aggregation inhibiting amounts of N,N,N-trimethylsphingosine.

18. The method of claim 17, wherein said platelet aggregation is induced by a cancer cell.

19. A medicament comprising:

- 5 (a) a platelet aggregation inhibiting amount of N,N,N-trimethylsphingosine or pharmaceutically acceptable salt thereof; and
- (b) a pharmaceutically acceptable carrier, diluent or excipient.

20. A composition comprising:

- 5 (a) a platelet aggregation inhibiting amount of N,N,N-trimethylsphingosine; and
- (b) a carrier, diluent or buffer.

21. A therapeutic method comprising administering to a host in need of treatment of a

cell proliferation inhibiting amounts of N,N,N-trimethylsphingosine or a pharmaceutically acceptable salt thereof.

22. A therapeutic method comprising administering to a host in need of treatment of a platelet aggregation inhibiting amounts of N,N,N-trimethylsphingosine or a pharmaceutically acceptable salt thereof.

23. A method of modulating intercellular contact comprising exposing cells to a biologically effective amount of N,N-dimethylsphingosine or N,N,N-trimethylsphingosine wherein said biologically effective amount is an amount that inhibits the expression or function of a cell adhesion molecule.

24. The method of claim 23, wherein said cells are selected from the group consisting of immune system cells, endothelial cells, tumor cells and platelets.

25. The method of claim 23, wherein said adhesion molecule is a selectin.

26. The method of claim 25, wherein said selecting is ELAM or GMP-140.

27. The method of claim 23 which comprises N,N-dimethylsphingosine.

28. The method of claim 23 which comprises N,N,N-trimethylsphingosine.

29. A therapeutic method for moderating inflammatory reactions comprising administering to a host in need of treatment an amount of N,N,N-trimethylsphingosine, or a pharmaceutically acceptable salt thereof, capable of inhibiting neutrophil activity.

30. The method of claim 29 wherein said amount is capable of inhibiting neutrophil

transendothelium migration.

31. The method of claim 29 wherein said amount is capable of inhibiting neutrophil superoxide production.

32. A therapeutic method for minimizing tissue damage resulting from superoxide exposure comprising administering to a host in need of treatment an amount of N,N,N-trimethylsphingosine, or a pharmaceutically acceptable salt thereof, capable of inhibiting neutrophil superoxide production.

33. A method for controlling neutrophil metabolism comprising exposing neutrophils to an activity inhibiting amount of N,N,N-trimethylsphingosine.

34. The method of claim 33 wherein said amount inhibits neutrophil superoxide production.

35. The method of claim 33 wherein said amount inhibits neutrophil migration.

36. A method of storing biologic material comprising exposing said material to a cell growth inhibiting amount of N,N,N-trimethylsphingosine.

37. The method of claim 36 wherein said biologic material is blood or a blood product.

1/16




FIG. 1




FIG. 2C




FIG. 2B




FIG. 2A

3/16




FIG. 3

4/16




FIG. 4B




FIG. 4A

5/16




FIG. 5A




FIG. 5B

6/16




FIG. 6A




FIG. 6B

SUBSTITUTE SHEET

7/16




FIG. 6C

8/16




FIG. 7A




FIG. 7B

9/16




FIG. 8

10/16




FIG. 9

11/16




FIG. 10

12/16




FIG. 11B




FIG. 11A




FIG. 12B




FIG. 12A

14/16




FIG. 13A

15/16




FIG. 13B

16/16




FIG. 14

INTERNATIONAL SEARCH REPORT

International Application No. PCT/US91/09196

I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all) *

According to International Patent Classification (IPC) or to both National Classification and IPC

IPC(5): C07C 215/40; C12N 5/00

U.S. CL.: 435/240.1, 240.2; 514/642; 564/292, 503

II. FIELDS SEARCHED

Minimum Documentation Searched *

Classification System

Classification Symbols

U.S. CL. 435/240.1, 240.2, 514/642; 564/292, 503

Documentation Searched other than Minimum Documentation
to the Extent that such Documents are Included in the Fields Searched *

CAS ONLINE: STRUCTURAL SEARCH

III. DOCUMENTS CONSIDERED TO BE RELEVANT *

Category *	Citation of Document, * with indication, where appropriate, of the relevant passages **	Relevant to Claim No. **
A	Science, Vol. 235, 1987, HANNUN et al. "Lysosphingolipids inhibit protein kinase C: implications for the sphingolipidoses", pages 670-674.	1-37

* Special categories of cited documents: **

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"A" document member of the same patent family

IV. CERTIFICATION

Date of the Actual Completion of the International Search

24 MARCH 1992

International Searching Authority

ISA/US

Date of Mailing of this International Search Report

09 APR 1992

Signature of Authorized Officer

RICHARD L. RAYMOND